About Thymosin Alpha 1

Thymosin Alpha 1 (TA1, sometimes Tα1) is a 28-amino-acid peptide produced naturally by the thymus gland. Its biological role is in T-cell maturation and immune modulation — particularly the differentiation of CD4+ T-helper cells and the regulation of innate immune responses. Synthetic TA1 has been studied (and clinically approved in many countries as Zadaxin) for chronic viral hepatitis, immune-compromised states, and as an adjunct in oncology research.

Unlike the recovery-focused peptides (BPC-157, TB-500), TA1 is an immune modulator rather than a tissue regenerator. Its mechanism is centred on Toll-like receptor 9 (TLR9) signalling and the resulting cytokine cascade. It’s the most-studied immune peptide in clinical literature with formal regulatory approval in over 30 countries.

Dosing observed in research literature

Application	Dose	Frequency	Notes
Standard research dose	1.6 mg	Twice weekly	Approved clinical dose for hepatitis B/C
Loading protocol	1.6 mg	Daily for 1–2 weeks	Used at protocol start in some research
Maintenance research dose	1.6 mg	Twice weekly	Standard maintenance for chronic protocols

Cycle length in research typically runs 6–12 months for immune-modulation protocols. TA1 doesn’t appear to cause receptor desensitisation, so continuous use is documented in clinical literature without dose escalation. Off-periods aren’t strictly required but are sometimes used to assess endogenous immune function in research designs.

Typical reconstitution protocols

TA1 typically ships as a 1.6 mg or 10 mg lyophilised vial:

Vial size	BAC water	Concentration	1.6 mg draw	Doses per vial
1.6 mg	1 mL	1.6 mg/mL	100 units (full barrel)	1 (single-use)
10 mg	2 mL	5 mg/mL	32 units	~6 doses
10 mg	2.5 mL	4 mg/mL	40 units	~6 doses
10 mg	5 mL	2 mg/mL	80 units	~6 doses

The 10 mg vial + 2 mL BAC water (5 mg/mL) is the practical sweet spot — keeps a 1.6 mg dose at 32 units on a U-100 syringe, lasts about 3 weeks at twice-weekly dosing, well within the 28-day BAC water window.

Half-life and frequency

Plasma half-life of TA1 is approximately 2 hours. Despite the short plasma window, the immune-modulating effect (T-cell maturation, cytokine response) operates on a much longer biological timescale — days to weeks. This is why twice-weekly dosing is sufficient despite the short plasma clearance: the receptor-level effect is what matters, not sustained plasma exposure.

Storage and shelf life

Lyophilised: store at 2–8°C refrigerated. Reconstituted with bacteriostatic water: stable for up to 28 days refrigerated. Some clinical preparations specify shorter post-reconstitution windows (14–21 days) — check supplier-specific guidance. Never freeze a reconstituted vial.

Frequently asked questions

What’s TA1 typically researched for?

Chronic hepatitis B and C are the original approved applications. Research extends to immune dysfunction, oncology adjunct therapy (combined with chemotherapy in some protocols), sepsis-related immune dysregulation, and more recently long-COVID immune research. The common thread is T-cell function modulation.

Does TA1 boost or suppress the immune system?

Modulates rather than simply boosts. TA1’s net effect depends on the baseline state — in immunocompromised research subjects it enhances T-cell function; in cytokine-storm states, it appears to normalise rather than further inflate the response. This bidirectional modulation distinguishes it from generalised immune stimulants.

Are there autoimmune contraindications?

Caution warranted in research with subjects having active autoimmune conditions. TA1’s enhancement of T-cell responses could theoretically worsen autoimmune-driven inflammation. Clinical trials typically exclude these populations.

Can TA1 be stacked with other peptides?

TA1 is commonly combined with BPC-157 in recovery-focused protocols (immune modulation + tissue repair). It’s also compatible with growth-hormone-axis peptides since the mechanisms don’t overlap. There’s no documented interaction with most other research peptides.

How long until effects are measurable?

Immunological biomarkers (CD4/CD8 ratios, specific cytokine levels) typically show changes within 4–8 weeks. Clinical endpoints (viral load reduction in hepatitis research, for example) require 3–6 months for measurable change. TA1 is a slow-acting compound by design.

What injection site is used?

Subcutaneous injection is standard, abdomen preferred. The twice-weekly dosing means site rotation is naturally distributed across days, but using different quadrants per injection is still recommended over a multi-month protocol.

Related compounds

TA1 sits in the recovery/healing research category as the primary immune-modulation compound. Adjacent: BPC-157 (tissue repair, often stacked), TB-500 (cell migration, recovery overlap), LL-37 (antimicrobial host-defense peptide). For full category overview: Healing & Recovery Peptides.